Trial Profile
A proof-of-concept trial of RGLS-4326
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 17 May 2018
Price :
$35
*
At a glance
- Drugs RGLS 4326 (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Proof of concept; Therapeutic Use
- 17 May 2018 New trial record
- 10 May 2018 According to a Regulus Therapeutics media release, this study is estimated for initiation in the second half of 2019.